Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05130866 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
A Phase 2 study, sponsored by Recursion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT05130866 is a Phase 2 study that was terminated before completion, run by Recursion Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT05130866, a Phase 2 study, was terminated before completion, sponsored by Recursion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in participants with progressive NF2 mutated meningiomas.
Interventions
- DRUG Placebo
- DRUG REC-2282
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-06-20 |
| Est. Completion | 2025-08-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05130866
The ClinicalTrials.gov registry entry for NCT05130866 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Recursion Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05130866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05130866 about?
NCT05130866 is a clinical study titled "Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas". This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in participants with progressive NF2 mutated meningiomas.
What is the current status of trial NCT05130866?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2022-06-20. Estimated completion is 2025-08-18.
What interventions are being tested in trial NCT05130866?
The interventions under investigation include: Placebo (DRUG), REC-2282 (DRUG).
Who is sponsoring clinical trial NCT05130866?
This trial is sponsored by Recursion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.